Clinical Trial Update: Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and pharmacokinetics of PC-1005 administered rectally in HIV-seronegative adults; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• PC-1005

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2023-04-14